NCT07070349

A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors

A Phase I/II Clinical Study to Evaluate the Safety, Radiation Dosimetry, Pharmacokinetics, and Preliminary Diagnostic Efficacy of HRS-6213 in Healthy Subjects and Patients With Solid Tumors

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Jiangsu HengRui Medicine Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The study is being conducted to evaluate the safety, radiation dosimetry, pharmacokinetics, and preliminary diagnostic efficacy of HRS-6213.

Conditions

• Patients With Solid Tumors

Interventions

Type	Name	Description
DRUG	HRS-6213	HRS-6213 IV administered as imaging agent for PET scan.

Timeline

• Start date: 2025-07-10
• Primary completion: 2026-01-01
• Completion: 2026-03-01
• First posted: 2025-07-17
• Last updated: 2025-08-12

Locations

1 site across 1 country: China